Sign in
CompletedPhase 2

A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia

Key facts

Who runs it
Beijing InnoCare Pharma Tech Co., Ltd.
Where
China16 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
47 people enrolled
Started
10 Aug 2019
Ended
9 Jan 2024
Type of study
Interventional
Treatments tested
  • ICP-022
Record updated
18 April 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (10)Hide the full registry criteria

Who can take part

  • Clinical and histologically confirmed giant globulinemia Fahrenheit (WM Ii International Working Group Standards, IWWM-2, 2003) (Owen et al., 2003)
  • At least one treatment indication is met (7th WM International Working Group standards, IWWM-7) (Dimopoulos et al., 2014)
  • With the lowest serum IgM value >2 times ULN as the efficacy evaluation index
  • ECOG physical strength score 0-2
  • Voluntary written informed consent prior to trial screening

Who cannot take part

  • Patients who had received autologous stem cell transplantation within the previous 6 months
  • Present or prior history of other malignant neoplasms, unless radical treatment has been performed and there is no evidence of recurrence or metastasis in the last 5 years
  • Demonstrate disease transformation
  • A history of organ transplantation or allogeneic bone marrow transplantation; NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
  • Amyloidosis and central nervous system (CNS) involvement caused by WM

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022.

Read full original descriptionShow less

Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R WM will be evaluated in approximately 44 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects.

The group in the trial

  • ICP-022Treatment being tested

    Subjects will take ICP-022 150mg once daily (QD).

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Open Clinical Trial to Evaluate the Safety and Efficacy of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia (WM)
Publications
Record updated
18 April 2024